Genitourinary Cancer
Nurse Takeaways: 2022 ASCO Genitourinary Cancers Symposium at a Glance
April 21, 2022
Article
PARP inhibitors emerge as frontline treatment in metastatic castration-resistant prostate cancer, immunotherapy combinations improve quality of life in advanced renal cell carcinoma, and antibody drug conjugates show promise in cisplatin-ineligible urothelial cancer.
Investigators Inch Closer to Unlocking CAR T-Cell Therapy Potential in Solid Tumors
April 13, 2022
Article
Findings from a phase 1 trial evaluating CAR T-cell therapy in patients with solid tumors showed promising clinical benefit with the treatment strategy.
Carbone Cancer Center Expert Shares Biggest Updates in Kidney Cancer Treatment
April 01, 2022
Podcast
In this episode of “The Vitals,” Hamid Emamekhoo, MD, discusses the evolving treatment landscape of kidney cancer.
FDA Approves 177Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
March 24, 2022
Article
Lutetium-177-PSMA-617 is now FDA-approved for the treatment of patients with metastatic castration-resistant prostate cancer who have already received androgen receptor pathway inhibition and taxane-based chemotherapy.
Radiotherapy Treatments Continue With Patient-Friendly Focus in Prostate Cancer
March 18, 2022
Article
Radiotherapy treatment has continued to evolve to become both shorter and faster in potentially curing prostate cancer.
Metastatic Urothelial Cancer Treatments Continue to Gravitate Towards Immunotherapy and Targeted Therapies
March 16, 2022
Article
A Yale Cancer Center expert offers a quick glance at the metastatic urothelial cancer treatment landscape.
Neoadjuvant Enfortumab Vedotin Shows Potential in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
February 28, 2022
Article
Preliminary findings suggest that enfortumab vedotin may be an effective treatment option for cisplatin-ineligible patients with muscle-invasive bladder cancer.
Adjuvant Mitotane Misses RFS End Point in Adrenocortical Carcinoma
February 27, 2022
Article
Adjuvant mitotane did not yield a significantly reduced risk of recurrence among patients with adrenocortical carcinoma.
5-Year Follow-Up Confirms Health-Related QOL Benefit With Nivolumab/Ipilimumab in Advanced RCC
February 25, 2022
Article
The immunotherapy combination of nivolumab and ipilimumab elicited favorable health-related quality of life responses compared with sunitinib in patients with advanced renal cell carcinoma.
Olaparib Is Linked With Decreased Pain Burden in Metastatic Castration-Resistant Prostate Cancer
February 25, 2022
Article
Compared with enzalutamide or abiraterone acetate tablets, olaparib was associated with decreased pain burden and better health-related quality of life in patients with castration-resistant prostate cancer.